sur Vascular Therapies
Vascular Therapies Completes Enrollment in Phase III ACCESS 2 Study for Sirogen
Vascular Therapies has announced the completion of enrollment in the ACCESS 2 trial, a Phase III multinational randomized clinical study evaluating Sirogen. This study aims to improve outcomes for arteriovenous (AV) fistula creation in hemodialysis patients.
Sirogen, a proprietary sirolimus formulation, has shown promise in improving fistula maturation and secondary patency compared to standard care in previous studies. ACCESS 2 seeks to validate these findings with 12_ patients across 18 centers in the U.S. and U.K. Topline results, including clinical fistula maturation at six months, are expected in Q2 2025.
Vascular Therapies CEO, John McDermott, expressed confidence in Sirogen’s potential to reduce failure rates and reinterventions, thus lowering patient morbidity and healthcare costs. Chief Scientific Officer, Sriram Iyer, emphasized the importance of this study in addressing unmet clinical needs.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Vascular Therapies